Tag : HIV1

AI/ML

Detection of HIV-1 viral load in tears of HIV/AIDS patients.

Newsemia
Related Articles Detection of HIV-1 viral load in tears of HIV/AIDS patients. Infection. 2020 Aug 26;: Authors: Qian Y, Wu Z, Chen C, Du K,...
Latest News

Cinical and biological disease progression in children with vertically-acquired HIV-1 infection in Europe: Statistical determinations

Newsemia
Gray, Linsay Anne; (2003) Cinical and biological disease progression in children with vertically-acquired HIV-1 infection in Europe: Statistical determinations. Doctoral thesis (Ph.D), UCL (University College...
AI/ML

Determination of RNA structural diversity and its role in HIV-1 RNA splicing.

Newsemia
Related Articles Determination of RNA structural diversity and its role in HIV-1 RNA splicing. Nature. 2020 Jun;582(7812):438-442 Authors: Tomezsko PJ, Corbin VDA, Gupta P, Swaminathan...
AI/ML

Drug Resistance Prediction Using Deep Learning Techniques on HIV-1 Sequence Data.

Newsemia
Related Articles Drug Resistance Prediction Using Deep Learning Techniques on HIV-1 Sequence Data. Viruses. 2020 May 19;12(5): Authors: Steiner MC, Gibson KM, Crandall KA Abstract...
Latest News

Gilead Sciences Presents Data Supporting a Potential Six-Month Dosing Interval for Investigational HIV-1 Capsid Inhibitor Lenacapavir (GS-6207)

Newsemia
FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from an ongoing Phase 1 study, which showed that a sustained-delivery subcutaneous formulation of...
AI/ML

Characterizing Protein-Ligand Binding Using Atomistic Simulation and Machine Learning: Application to Drug Resistance in HIV-1 Protease.

Newsemia
Related Articles Characterizing Protein-Ligand Binding Using Atomistic Simulation and Machine Learning: Application to Drug Resistance in HIV-1 Protease. J Chem Theory Comput. 2020 Feb 11;16(2):1284-1299...
AI/ML

Three Major Phosphoacceptor Sites in HIV-1 Capsid Protein Enhances its Structural Stability and Resistance against Inhibitor: Explication through Molecular Dynamics Simulation, Molecular Docking and DFT Analysis.

Newsemia
Related Articles Three Major Phosphoacceptor Sites in HIV-1 Capsid Protein Enhances its Structural Stability and Resistance against Inhibitor: Explication through Molecular Dynamics Simulation, Molecular Docking...
Latest News

The Safety and Immunogenicity of GTU (R) MultiHIV DNA Vaccine Delivered by Transcutaneous and Intramuscular Injection With or Without Electroporation in HIV-1 Positive Subjects on Suppressive ART

Newsemia
Haidari, G; Day, S; Wood, M; Ridgers, H; Cope, A; Fleck, S; Yan, C; … Shattock, RJ; + view all Haidari, G; Day, S; Wood,...
Pharma / Biotech

Raltegravir (RAL) in neonates: Dosing, pharmacokinetics (PK), and safety in HIV-1 exposed neonates at risk of infection (IMPAACT P1110).

Newsemia
Raltegravir (RAL) in neonates: Dosing, pharmacokinetics (PK), and safety in HIV-1 exposed neonates at risk of infection (IMPAACT P1110). J Acquir Immune Defic Syndr. 2020...
AI/ML

HIVCoR: A sequence-based tool for predicting HIV-1 CRF01_AE coreceptor usage.

Newsemia
Related Articles HIVCoR: A sequence-based tool for predicting HIV-1 CRF01_AE coreceptor usage. Comput Biol Chem. 2019 Jun;80:419-432 Authors: Hongjaisee S, Nantasenamat C, Carraway TS, Shoombuatong...
AI/ML

Drivers of HIV-1 transmission: The Portuguese case.

Newsemia
Related Articles Drivers of HIV-1 transmission: The Portuguese case. PLoS One. 2019;14(9):e0218226 Authors: Pineda-Peña AC, Pingarilho M, Li G, Vrancken B, Libin P, Gomes P,...
Pharma / Biotech

Safety, Tolerability, and Pharmacokinetics of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 in HIV-Exposed Newborn Infants.

Newsemia
Related Articles Safety, Tolerability, and Pharmacokinetics of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 in HIV-Exposed Newborn Infants. J Infect Dis. 2019 Nov 04;: Authors:...
Latest News

ViiV Healthcare announces phase III study meets primary endpoint, demonstrating the ability to control HIV-1 with a 2-drug regimen of dolutegravir plus lamivudine in virally suppressed patients switching from a TAF-containing, 3-drug regimen

Newsemia
LONDON–(BUSINESS WIRE)–ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced positive Week 48 results...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World